Click aici pentru detalii

investigators. N Engl J Med 1996; 335: 1001-9.
[140] Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of initial
cholesterol levels. The Long-Term Intervention with Pravastatin in
Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:
1349-57.
[141] Marchioli R, Valagussa F. The results of the
GISSIPrevenzione trial in the general framework of secondary
prevention. Eur Heart J 2000; 21: 949-52.
[142] Yusuf S, Collins R, MacMahon S, Peto R. Effect of
intravenous nitrates on mortality in acute myocardial infarction: an
overview of the randomised trials. Lancet 1988; 1: 1088-92.
[143] Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC.
A comparison of results of meta-analyses of randomized control trials
and recommendations of clinical experts. Treatments for myocardial
infarction. JAMA 1992; 268: 240-8.
[144] Teo KK, Yusuf S. Role of magnesium in reducing mortality in
acute myocardial infarction. A review of the evidence. Drugs 1993; 46:
347-59.
[145] Woods KL, Fletcher S. Long-term outcome after intravenous
magnesium sulphate in suspected acute myocardial infarction: the
second Leicester Intravenous Magnesium Intervention Trial (LIMIT-
2). Lancet 1994; 343: 816-19.
[146] Antman EM. Randomized trials of magnesium in acute
myocardial infarction: big numbers do not tell the whole story. Am J
Cardiol 1995; 75: 391-3.
[147] Efectiveness of intravenous thrombolytic treatment in acute
myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico (GISSI). Lancet 1986; 1: 397-402.
[148] Wilcox RG, von der LG, Olsson CG, Jensen G, Skene AM,
Hampton JR. Effects of alteplase in acute myocardial infarction: 6month
results from the ASSET study. Anglo- Scandinavian Study of
Early Thrombolysis. Lancet 1990; 335: 1175-8.
[149] A prospective trial of intravenous streptokinase in acute
myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct
size at 21 days. The I.S.A.M. Study Group. N Engl J Med 1986; 314:
1465-71.
[150] Long-term effects of intravenous anistreplase in acute
myocardial infarction: final report of the AIMS study. AIMS Trial
Study Group. Lancet 1990; 335: 427-31.
[151] In-hospital mortality and clinical course of 20.891 patients
with suspected acute myocardial infarction randomised between
alteplase and streptokinase with or without heparin. The International
Study Group. Lancet 1990; 336: 71-5.
[152] ISIS-3: a randomised comparison of streptokinase vs tissue
plasminogen activator vs anistreplase and of aspirin plus heparin vs
aspirin alone among 41.299 cases of suspected acute myocardial
infarction. ISIS-3 (Third International Study of Infarct Survival)
Collaborative Group. Lancet 1992; 339: 753-70.
[153] An international randomized trial comparing four
thrombolytic strategies for acute myocardial infarction. The GUSTO
investigators. N Engl J Med 1993; 329: 673-82.
[154] Cannon CP, McCabe CH, Diver DJ et al. Comparison of
front-loaded recombinant tissue-type plasminogen activator,
anistreplase and combination thrombolytic therapy for acute
myocardial infarction: results of the Thrombolysis in Myocardial
Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24: 1602-10.
[155] Granger CB, Cali. RM, Topol EJ. Thrombolytic therapy for
acute myocardial infarction. A review. Drugs 1992; 44: 293-325.
[156] Collaborative overview of randomised trials of antiplatelet
therapy - I: Prevention of death, myocardial infarction, and stroke by
prolonged antiplatelet therapy in various categories of patients.
Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81-106.
[157] Hass WK, Easton JD, Adams HP et al. A randomized trial
comparing ticlopidine hydrochloride with aspirin for the prevention of
stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
64
N Engl J Med 1989; 321: 501-7.
[158] Effect of long-term oral anticoagulant treatment on mortality
and cardiovascular morbidity after myocardial infarction.
Anticoagulants in the Secondary Prevention of Events in Coronary
Thrombosis (ASPECT) Research Group. Lancet 1994; 343: 499-503.
[159] Smith P, Arnesen H, Holme I. The effect of warfarin on
mortality and reinfarction after myocardial infarction. N Engl J Med
1990; 323: 147-52.
[160] A controlled comparison of aspirin and oral anticoagulants in
prevention of death after myocardial infarction. N Engl J Med 1982;
307: 701-8.
[161] Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery
bypass graft surgery on survival: overview of 10-year results from
randomised trials by the Coronary Artery Bypass Graft Surgery
Trialists Collaboration. Lancet 1994; 344: 563-70.
[162] Invasive compared with non-invasive treatment in unstable
coronary-artery disease: FRISC II prospective randomised multicentre
study. FRagmin and Fast Revascularization during InStability in
Coronary artery disease Investigators. Lancet 1999; 354: 708-15.
[163] Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E,
Swahn E. Outcome at 1 year after an invasive compared with a noninvasive
strategy in unstable coronary-artery disease: the FRISC II
invasive randomised trial. FRISC II Investigators. Fast
Revascularization during Instability in Coronary artery disease. Lancet
2000; 356: 9-16.
[164] Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF,
Harris PJ. Infarct artery perfusion and changes in left ventricular
volume in the month after acute myocardial infarction. J Am Coll
Cardiol 1987; 9: 989-95.
[165] Pizzetti G, Belotti G, Margonato A, Cappelletti A, Chierchia
SL. Coronary recanalization by elective angioplasty prevents
ventricular dilation after anterior myocardial infarction. J Am Coll
Cardiol 1996; 28: 837-45.
[166] Myocardial infarction redefined - A consensus document of
the Joint European Society of Cardiology/American College of
Cardiology Committee for the Redefinition of Myocardial Infarction.
Eur Heart J 2000; 21: 1502-13.
[167] Topol EJ, Ferguson JJ, Weisman HF et al. Long-term
protection from myocardial ischemic events in a randomized trial of
brief integrin beta3 blockade with percutaneous coronary intervention.
EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for
Prevention of Ischemic Complication. JAMA 1997; 278: 479-84.
[168] Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers
WJ. Clinical experience with primary percutaneous transluminal
coronary angioplasty compared with alteplase (recombinant tissue-type
plasminogen activator) in patients with acute myocardial infarction: a
report from the Second National Registry of Myocardial Infarction
(NRMI-2). J Am Coll Cardiol 1998; 31: 1240-5.
[169] Stone GW, Brodie BR, Gri.n JJ et al. Prospective, multicenter
study of the safety and feasibility of primary stenting in acute
myocardial infarction: in-hospital and 30-day results of the PAMI
stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent
Pilot Trial Investigators. J Am Coll Cardiol 1998; 31: 23-30.
[170] Maillard L, Hamon M, Khalife K et al. A comparison of
systematic stenting and conventional balloon angioplasty during
primary percutaneous transluminal coronary angioplasty for acute
myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol
2000; 35: 1729-36.
[171] Grines CL, Cox DA, Stone GW et al. Coronary angioplasty
with or without stent implantation for acute myocardial infarction.
Stent Primary Angioplasty in Myocardial Infarction Study Group. N
Engl J Med 1999; 341: 1949-56.
[172] Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebocontrolled
trial of platelet glycoprotein IIb/IIIa blockade with primary
angioplasty for acute myocardial infarction. Reo Pro and Primary
PTCA Organization and Randomized Trial (RAPPORT)
REVISTA ROMÅN~ DE CARDIOLOGIE Vol. XIX, Nr. 1, An 2004